Literature DB >> 35405517

Association between use of enhanced recovery after surgery protocols and postoperative complications in colorectal surgery in Europe: The EuroPOWER international observational study.

Javier Ripollés-Melchor1, Ane Abad-Motos2, Maurizio Cecconi3, Rupert Pearse4, Samir Jaber5, Karem Slim6, Nader Francis7, Antonino Spinelli3, Jean Joris8, Orestis Ioannidis9, Eirini Zarzava10, Nüzhet Mert Şentürk11, Seppe Koopman12, Nicolai Goettel13, Ottokar Stundner14, Tomas Vymazal15, Petr Kocián16, Alaa El-Hussuna17, Michał Pędziwiatr18, Jurate Gudaityte19, Tadas Latkauskas20, Marisa D Santos21, Humberto Machado22, Roman Zahorec23, Ana Cvetković24, Mirjana Miric25, Maria Georgiou26, Yolanda Díez-Remesal27, Ib Jammer28, Gabriel E Mena29, Andrés Zorrilla-Vaca30, Marco V Marino31, Alejandro Suárez-de-la-Rica32, José A García-Erce33, Margarita Logroño-Ejea34, Carlos Ferrando-Ortolá35, María L De-Fuenmayor-Valera36, Bakarne Ugarte-Sierra37, José de Andrés-Ibañez38, Alfredo Abad-Gurumeta36, Gianluca Pellino39, Manuel A Gómez-Ríos40, Gilberto Poggioli41, Albert Menzo-Wolthuis42, Berta Castellano-Paulis43, Patricia Galán-Menéndez44, César Aldecoa45, José M Ramírez-Rodríguez46.   

Abstract

STUDY
OBJECTIVE: Assess the relationship between the Enhanced Recovery After Surgery (ERAS®) pathway and routine care and 30-day postoperative outcomes.
DESIGN: Prospective cohort study.
SETTING: European centers (185 hospitals) across 21 countries. PATIENTS: A total of 2841 adult patients undergoing elective colorectal surgery. Each hospital had a 1-month recruitment period between October 2019 and September 2020.
INTERVENTIONS: Routine perioperative care. MEASUREMENTS: Twenty-four components of the ERAS pathway were assessed in all patients regardless of whether they were treated in a formal ERAS pathway. A multivariable and multilevel logistic regression model was used to adjust for baseline risk factors, ERAS elements and country-based differences.
RESULTS: A total of 1835 patients (65%) received perioperative care at a self-declared ERAS center, 474 (16.7%) developed moderate-to-severe postoperative complications, and 63 patients died (2.2%). There was no difference in the primary outcome between patients who were or were not treated in self-declared ERAS centers (17.1% vs. 16%; OR 1.00; 95%CI, 0.79-1.27; P = 0.986). Hospital stay was shorter among patients treated in self-declared ERAS centers (6 [5-9] vs. 8 [6-10] days; OR 0.82; 95%CI, 0.78-0.87; P < 0.001). Median adherence to 24 ERAS elements was 57% [48%-65%]. Adherence to ERAS-pathway quartiles (≥65% vs. <48%) suggested that patients with the highest adherence rates experienced a lower risk of moderate-to-severe complications (15.9% vs. 17.8%; OR 0.71; 95%CI, 0.53-0.96; P = 0.027), lower risk of death (0.3% vs. 2.9%; OR 0.10; 95%CI, 0.02-0.42; P = 0.002) and shorter hospital stay (6 [4-8] vs. 7 [5-10] days; OR 0.74; 95%CI, 0.69-0.79; P < 0.001).
CONCLUSIONS: Treatment in a self-declared ERAS center does not improve outcome after colorectal surgery. Increased adherence to the ERAS pathway is associated with a significant reduction in overall postoperative complications, lower risk of moderate-to-severe complications, shorter length of hospital stay and lower 30-day mortality.
Copyright © 2022 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Colorectal surgery; ERAS; Enhanced recovery; Optimization; Perioperative management; Postoperative complications

Mesh:

Year:  2022        PMID: 35405517     DOI: 10.1016/j.jclinane.2022.110752

Source DB:  PubMed          Journal:  J Clin Anesth        ISSN: 0952-8180            Impact factor:   9.452


  2 in total

1.  Model-Based Computational Analysis on the Effectiveness of Enhanced Recovery after Surgery in the Operating Room with Nursing.

Authors:  Wenji Li; Shu Huang; Yong Xie; Guanyu Chen; Jun Yuan; Yun Yang
Journal:  Front Surg       Date:  2022-05-18

2.  Multiple interventional embolizations for hemostasis in hemorrhage following advanced colorectal cancer treatment: a case report.

Authors:  Dongqiang Yang; Bo Shi; Yazhou Li; Yu Zhao; Ping Shi; Zhigang Li
Journal:  J Gastrointest Oncol       Date:  2022-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.